A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 596
Last updated 2025-12-18
Summary
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
Conditions
- Episodic Migraine
- Chronic Migraine
Interventions
- DRUG
-
Atogepant 60 mg
Tablets containing 60 mg of Atogepant
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-02-19
- Primary Completion
- 2025-10-20
- Completion
- 2025-10-20
- FDA Drug
- Yes
Countries
- United States
- Canada
- Czechia
- Denmark
- France
- Germany
- Hungary
- Italy
- Netherlands
- Poland
- South Korea
- Spain
- Taiwan
- United Kingdom
Study Locations
More Related Trials
-
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
NCT03777059 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505 ·Status: RECRUITING ·Phase: PHASE3
-
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914 ·Status: RECRUITING
-
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
NCT04740827 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
NCT05264129 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394 ·Status: RECRUITING ·Phase: PHASE3
-
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
NCT06882122 ·Status: RECRUITING
-
Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine
NCT04829747 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
NCT05216263 ·Status: COMPLETED ·Phase: PHASE3
-
Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine
NCT04818515 ·Status: COMPLETED ·Phase: PHASE1
-
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
NCT05653986 ·Status: COMPLETED
-
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
NCT05861427 ·Status: COMPLETED ·Phase: PHASE3
-
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
NCT06603558 ·Status: RECRUITING
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750 ·Status: RECRUITING
-
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
NCT06414044 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
NCT05518123 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT06972056 ·Status: RECRUITING ·Phase: PHASE4
-
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
NCT06701526 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02828020 ·Status: COMPLETED ·Phase: PHASE3
-
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
NCT02873221 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02867709 ·Status: COMPLETED ·Phase: PHASE3